Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.